Psychiatry · SSRIRegulatory Approvalregulatorymid-term

FDA Accepts ANDA for Fluvoxamine Maleate by APPCO

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/11/2026, 6:32:27 PM

Assessment confidence: 71% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of APPCO's ANDA for Fluvoxamine Maleate signals increased competition in the SSRI market, which could impact pricing and market share for existing products. Portfolio teams must evaluate the implications for their SSRIs and adjust strategies accordingly. Regulatory context from FDA (FDA AP — FLUVOXAMINE MALEATE (ORIG)) supports the near-term read. Assessment grounded in 13 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact on market share and pricing strategies for existing SSRIs. The strongest clinical anchor is MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (ClinicalTrials.gov), moderate corpus alignment. In Psychiatry · SSRI, 6 regulatory and 1 competitive items passed relevance filtering for APPCO.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). This acceptance may increase competition in the SSRI market, particularly against branded products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — FLUVOXAMINE MALEATE (ORIG) (FDA). Entity match (fluvoxamine maleate); Regulatory pathway relevance (nda). The acceptance of the ANDA indicates a regulatory pathway for APPCO, which could lead to market entry and further competition in the near future.

Key Risks

Elevated medium regulatory exposure for APPCO could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Increased competition may lead to pricing pressures on existing SSRIs, potentially affecting revenue and market share for established brands.
Upside for APPCO may improve if Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the potential impact on market share and pricing strategies for existing SSRIs.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for approval and any subsequent market entry by APPCO.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — FLUVOXAMINE MALEATE (ORIG)
FDAhigh relevance
Entity match (fluvoxamine maleate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FLUVOXAMINE MALEATE (ORIG)
FDAhigh relevance
Entity match (appco); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effects of Eccentric Compared to Standard Strength Training in Primary Spinal Cord Injury Rehabilitation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

APPCO
Fluvoxamine Maleate

Commercial impact

medium

Increased competition may lead to pricing pressures on existing SSRIs, potentially affecting revenue and market share for established brands.

Regulatory impact

medium

The acceptance of the ANDA indicates a regulatory pathway for APPCO, which could lead to market entry and further competition in the near future.

What to watch

Monitor the timeline for approval and any subsequent market entry by APPCO.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.